Philipp Mann

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Peter G. Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana‐Arri et al. · The Lancet Infectious Diseases · 2021 · 170 citations · Full text

Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2

Peter G. Kremsner, Philipp Mann, Arne Kroidl et al. · Wiener klinische Wochenschrift · 2021 · 130 citations · Full text

Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers

Peter G. Kremsner, Philipp Mann, Jacobus J. Bosch et al. · 2020 · 103 citations · Full text

Candidate Vaccine Cvncov, Viral Immunity, Immunology +17

Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

Lindsey R. Baden, Daniel J Stieh, Michal Sarnecki et al. · The Lancet HIV · 2020 · 90 citations · Full text

The Triple A Syndrome Is Due to Mutations in ALADIN, a Novel Member of the Nuclear Pore Complex

Angela Huebner, Angela M. Kaindl, Klaus‐Peter Knobeloch et al. · Endocrine Research · 2004 · 74 citations

Signal Transduction, Mendelian Disorder, Genetic Disorder +13